Conference Details - Agenda
View all Conferences
Continuing Education Information
Physicians: Physicians’ Education Resource is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians’ Education Resource designates this educational activity for a maximum of 29 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Physician Assistants: AAPA accepts category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA category 1 CME credit for the PRA from organizations accredited by the ACCME.
14th Annual International Congress on Hematologic Malignancies
The Fairmont Château Whistler
Whistler
March 17-21, 2010
| 12:00 pm |
Registration
|
| 4:00 pm |
Welcome and Introductions
|
| 4:15 pm |
Pharmacoeconomics and the Management of Hematologic Malignancies
Wayne A. Rosenkrans, Jr |
| 4:45 pm |
Dissection of Signaling in Follicular Lymphoma
Ronald Levy |
| 5:15 pm |
Update on Indolent Lymphoma
David Maloney |
| 5:45 pm |
Update on Aggressive Lymphoma
Wyndham H. Wilson |
| 6:15 pm |
Prognostic Factors in CLL
Thomas James Kipps |
| 6:45 pm |
Adjourn
|
| 7:00 pm |
Reception
|
| 6:30 am |
Continental Breakfast
|
| 7:00 am |
Presession Survey
|
| 7:10 am |
How I Manage Mantle Cell Lymphoma
Andrew D. Zelenetz |
| 7:25 am |
Comment
Michael Williams |
| 7:30 am |
How I Manage Follicular Lymphoma
Michael Williams |
| 7:45 am |
Comment
David Maloney |
| 7:50 am |
How I Manage Non-Follicular Indolent Lymphoma
Jane Winter |
| 8:05 am |
Comment
|
| 8:10 am |
How I Manage Diffuse Large B-Cell Lymphoma
Andrew M. Evens |
| 8:25 am |
Comment
Andrew D. Zelenetz |
| 8:35 am |
Panel Discussion
|
| 8:55 am |
Follicular Lymphoma
Discussants: Randy Gascoyne, David Maloney, Andrew D. Zelenetz |
| 9:55 am |
CON
Joseph M. Connors |
| 10:05 am |
PRO
Wyndham H. Wilson |
| 10:15am |
Postsession Survey and Panel Discussion
Joseph M. Connors, Wyndham H. Wilson |
| 10:30 am |
Adjourn
|
| 10:45 am |
Targeting Apoptosis
Andrew M. Evens |
| 11:05 am |
Targeting Apoptosis in Chronic Lymphocytic Leukemia
Thomas James Kipps |
| 11:25 am |
Targeting Epigenetics in Multiple Myeloma
Sundar Jagannath |
| 11:45 am |
Targeting Epigenetics in Non-Hodgkin Lymphoma
Youn Kim |
| 12:05 pm |
Abrogating the Cell Cycle in Chronic Lymphocytic Leukemia
Jeffrey Jones |
| 12:25 pm |
Adjourn
|
| 4:00 pm |
Challenges in the Management of Lymphoma in the Elderly
Paul Hamlin |
| 4:20 pm |
Presession Survey
|
| 4:25 pm |
Frontline Management of Hodgkin Lymphoma
Joseph M. Connors |
| 4:45 pm |
Management of Relapsed/Refractory Disease
Jane Winter |
| 5:05 pm |
Panel Discussion
Joseph M. Connors, Jane Winter |
| 5:15 pm |
Where Are We in the Management of Aggressive T-Cell Lymphoma?
Steven M. Horwitz |
| 5:35 pm |
Approaches to the Management of Cutaneous T-Cell Lymphoma
Youn Kim |
| 5:55 pm |
Panel Discussion
Steven M. Horwitz, Youn Kim |
| 6:05 pm |
Mantle Cell Lymphoma
Discussants: Randy Gascoyne, Sonali M. Smith, Michael Williams |
| 7:05 pm |
Postsession Survey
|
| 7:15 pm |
Adjourn
|
| 6:45 am-7:15 am |
Continental Breakfast/Meet the Professors
TBD |
| 7:20 am |
Presession Survey
|
| 7:30 am |
The Management of Polycythemia Vera and Essential Thrombocythemia
Ruben A. Mesa |
| 7:50 am |
What Would It Take to Displace Imatinib as First-line Treatment of Chronic Myeloid Leukemia?
Charles Schiffer |
| 8:10 am |
How to Monitor Response and When to Consider Changes in the Treatment of Patients With Chronic Myeloid Leukemia
Harry Erba |
| 8:30 am |
Are the Newer Molecular Prognostic Factors Useful in Selecting Treatments for Patients With Acute Myeloid Leukemia?
Martin S. Tallman |
| 8:50 am |
Have There Truly Been Advances in the Treatment of Myelodysplastic Syndromes?
David Steensma |
| 9:10 am |
Postsession Survey
|
| 9:15 am |
Question-and-Answer Session
|
| 9:30 am |
Panel Discussion: In the Absence of Randomized Trials, What Criteria Should Be Used to Approve New Drugs for the Treatment of Older Patients With Acute Myeloid Leukemia?
Harry Erba, Jerald P. Radich, Charles Schiffer, Martin S. Tallman |
| 10:00 am |
Adjourn
|
| 10:15 am |
New Targeted Agents in Multiple Myeloma
Keith Stewart |
| 10:35 am |
Novel Targeted Agents in Chronic Lymphocytic Leukemia
Jennifer R. Brown |
| 10:55 am |
mTOR Inhibitors in Lymphoma
Sonali M. Smith |
| 11:15 am |
New Drugs in the Treatment of Acute Myeloid Leukemia: A Critical Appraisal
Charles Schiffer |
| 11:35 am |
New Agents and Combinations for Myelodysplastic Syndromes
David Steensma |
| 11:55 am |
New Agents for CML
Jorge Cortes |
| 12:15 pm |
Adjourn
|
| 4:00 pm |
Presession Survey
|
| 4:05 pm |
Should All Patients With Acute Lymphoblastic Leukemia in First Remission Be Referred For Allogeneic Transplantation?
|
| 4:25 pm |
How Should Patients With Acute Promyelocytic Leukemia Be Managed?
Martin S. Tallman |
| 4:45 pm |
Is There a Role for the Monitoring of Minimal Residual Disease in Adults With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia?
Charles Schiffer |
| 5:05 pm |
Should Younger Patients With Higher-Grade Myelodysplastic Syndromes Be Treated With Induction Therapy or Referred Directly for Transplantation?
Jerald P. Radich |
| 5:25 pm |
Panel Discussion
|
| 5:45 pm |
PRO
Charles Schiffer |
| 6:00 pm |
CON
Harry Erba |
| 6:15 pm |
Commentary and Audience Discussion
Charles Schiffer |
| 6:35 pm |
Postsession Survey
|
| 6:40 pm |
Case-Based Panel Discussion
|
| 7:00 pm |
Adjourn
|
| 6:45 am-7:15 am |
Continental Breakfast/Meet the Professors
TBA |
| 7:20 am |
Presession Survey
|
| 7:30 am |
Keynote Lecture: Plasma Cell Disorders: From Amyloidosis to Waldenström Macroglobulinemia
Morie Gertz |
| 8:00 am |
How I Manage Newly Diagnosed Myeloma in Elderly Patients
Sagar Lonial |
| 8:20 am |
How I Manage Newly Diagnosed Transplantation-Eligible Myeloma
Donna Reece |
| 8:40 am |
Panel Discussion: Newly Diagnosed Myeloma Cases
Sundar Jagannath |
| 8:55 am |
How I Manage Relapsed/Refractory Myeloma
Jeffrey Zonder |
| 9:15 am |
What Promising New Therapies Are in Clinical Trials for Myeloma?
Keith Stewart |
| 9:35 am |
Panel Discussion: Relapsed/Refractory Myeloma Cases
G. David Roodman |
| 9:55 am |
Postsession Survey
|
| 10:00 am |
Adjourn
|
| 10:15 am |
New Concepts in Antibody Engineering
Jane Winter |
| 10:35 am |
New Antibodies in Multiple Myeloma
Sagar Lonial |
| 10:55 am |
New Antibodies in B-Cell Non-Hodgkin Lymphoma
David Maloney |
| 11:15 am |
New Antibodies in Hodgkin Lymphoma
Joseph Connors |
| 11:35 am |
Targeting Bone Health
G. David Roodman |
| 11:55 am |
Adjourn
|
| 4:00 pm |
Presession Survey
|
| 4:10 pm |
What's New in Chronic Lymphocytic Leukemia: Updates From ASCO, IWCLL, and ASH
Jennifer R. Brown |
| 4:40 pm |
A Primer on How to Use Diagnostic Tests in Patients With Newly Diagnosed Chronic Lymphocytic Leukemia
Thomas James Kipps |
| 5:00 pm |
The Best Initial Treatment for Chronic Lymphocytic Leukemia: A Case-Based Discussion
William G. Wierda |
| 5:20 pm |
Managing Autoimmune Complications in Chronic Lymphocytic Leukemia: A Case-Based Discussion
Clive S. Zent |
| 5:40 pm |
Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia: A Case-Based Discussion
Alessandra Ferrajoli |
| 6:00 pm |
What Are the New Drugs on the Horizon That My Patients Will Ask Me About?
Jeffrey Jones |
| 6:30 pm |
Panel Discussion
|
| 6:50 pm |
Postsession Survey
|
| 7:00 pm |
Adjourn
|
| 6:30 am |
Continental Breakfast
|
| 7:00 am - 9:00 am |
Acute Myeloid Leukemia/Myelodysplastic Syndromes
Acute Myeloid Leukemia/Myelodysplastic Syndromes
Chronic Myeloid Leukemia/Myeloproliferative Disorders
Chronic Lymphocytic Leukemia
Lymphoma
Multiple Myeloma |
| 9:00 am |
Adjourn
|
